Our focus on Myasthenia Gravis at AANEM 2020 | UCB
UCB's Global Corporate Website

Our focus on Myasthenia Gravis at AANEM 2020

Ahmad Alrawi, Neurology Patient Value Unit
Posted by
Ahmad Alrawi, Neurology Patient Value Unit

As we convene this year’s annual meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), it’s important to acknowledge how different this year’s event is – and to embrace the chance for us to connect digitally.

Although, this year, we might not be sharing the same physical space, we are no less committed to using this week to learn and collaborate with our peers to improve patient care. Throughout the meeting, UCB will be joining in conversations to advance support and care for those who live with rare conditions like generalized Myasthenia Gravis (gMG).  We are harnessing this opportunity to share research, insights and perspectives that we hope could improve the lives of people living with rare neuromuscular conditions.

We are proud to be sharing for the first time our “gMG Never Rests,” campaign at AANEM, an initiative which acknowledges the unique, unpredictable challenges patients with gMG can experience. The campaign is designed to help improve recognition of and communication about the burden of gMG and to better equip neurologists in addressing and responding to patient needs. In an AANEM Industry Forum, on Friday, October 9 from 9:15-10:15am CDT, we will be hosting MG experts and a patient with first hand lived MG experiences to discuss how the community can work together to better predict the unpredictable in gMG.

At UCB, we know that many patients with uncontrolled gMG live each day with a sense of instability as they cope with unpredictable, debilitating symptoms and worries about the risk of serious events related to their condition. Given the wide range of and fluctuating nature of gMG symptoms, it can be difficult for physicians to understand when a condition is under control. We hope “gMG Never Rests” will help patients feel supported and understood while navigating their own experiences.

Also at AANEM, UCB will be presenting an abstract titled “Treatment and Burden of MG: A Retrospective Study of a US Insurance Claims Database.” This study assessed the treatment patterns and burden of disease among patients with gMG. Despite current treatment options, the burden of disease remains high, which demonstrates a need for additional therapeutic options. The analysis will be presented on Saturday, October 10 at 3:15–3:45pm CDT.

AANEM offers a great moment for scientific exchange of the latest clinical and scientific developments in neuromuscular and electrodiagnostic medicine, and UCB is excited to be a part of advancing the treatment of neuromuscular conditions like gMG. Throughout the meeting we will be showcasing all of our activities via a virtual booth experience. Registered delegates can visit the booth to learn more about how UCB is building something bold for people living with Rare Diseases!

To everyone participating in the meeting we look forward to connecting with you over the coming days!

Leave a Comment

By submitting your personal data, you agree with UCB's Data Privacy Policy. Furthermore, for more information on the terms of use of this website please visit our Legal Notice, accessible here.
Enter the characters shown in the image.